These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30649751)

  • 21. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
    Sujobert P; Rioufol C; Salles GA
    Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
    Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
    Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
    Davies A
    Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Borazanci E; Pishvaian MJ; Nemunaitis J; Weekes C; Huang J; Rajakumaraswamy N
    Oncologist; 2020 Nov; 25(11):e1604-e1613. PubMed ID: 32356383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting phosphoinositide 3-kinase: moving towards therapy.
    Marone R; Cmiljanovic V; Giese B; Wymann MP
    Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K Inhibitors in Hematology: When One Door Closes….
    Skånland SS; Okkenhaug K; Davids MS
    Clin Cancer Res; 2024 Sep; 30(17):3667-3675. PubMed ID: 38967552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.
    Seiler T; Hutter G; Dreyling M
    Drugs; 2016 Apr; 76(6):639-46. PubMed ID: 27052260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary adverse events related to idelalisib therapy: A single centre experience.
    Migault C; Lebrun D; Toubas O; Nguyen Y; Giltat A; Julien G; Toubas D; Lebargy F; Delmer A; Bani-Sadr F
    J Chemother; 2018 Sep; 30(5):318-322. PubMed ID: 30299215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
    Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
    Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatidylinositol 3-kinase isoforms as novel drug targets.
    Błajecka K; Borgström A; Arcaro A
    Curr Drug Targets; 2011 Jun; 12(7):1056-81. PubMed ID: 21291386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
    Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Grave diarrhea associated with idelalisib administration].
    Suárez Del Olmo D; Corregidor Luna L; Hidalgo Correas FJ; García Benayas E; García Díaz B
    Farm Hosp; 2016 May; 40(3):227-9. PubMed ID: 27145392
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.
    Horak F; Puri KD; Steiner BH; Holes L; Xing G; Zieglmayer P; Zieglmayer R; Lemell P; Yu A
    J Allergy Clin Immunol; 2016 Jun; 137(6):1733-1741. PubMed ID: 26915677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.